^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TRK-950

    i
    Other names: TRK-950, TRK950, TRK 950
    Company:
    Toray
    Drug class:
    Caprin-1 inhibitor
    3ms
    A Study of TRK-950 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=19, Recruiting, Toray Industries, Inc | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • TRK-950
    3ms
    A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=187, Recruiting, Toray Industries, Inc | Trial completion date: Aug 2024 --> Mar 2025 | Trial primary completion date: Aug 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium • Zyclara (imiquimod) • TRK-950
    4ms
    A Study of TRK-950 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, Toray Industries, Inc
    Trial completion date • Trial primary completion date • Metastases
    |
    TRK-950
    4ms
    A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=169, Recruiting, Toray Industries, Inc
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • topotecan • leucovorin calcium • Zyclara (imiquimod) • TRK-950
    5ms
    A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with CAPRIN-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. (ASCO-GI 2024)
    4, suppl. Clinical trial information: NCT06038578.
    Clinical • P2 data • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • CAPRIN1 (Cell Cycle Associated Protein 1)
    |
    HER-2 positive • CAPRIN-1 expression
    |
    paclitaxel • Cyramza (ramucirumab) • TRK-950
    6ms
    A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=169, Recruiting, Toray Industries, Inc | Phase classification: P1b --> P1
    Phase classification • Metastases
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • topotecan • leucovorin calcium • Zyclara (imiquimod) • TRK-950
    7ms
    A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer (clinicaltrials.gov)
    P2, N=146, Recruiting, Toray Industries, Inc | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    CAPRIN1 (Cell Cycle Associated Protein 1)
    |
    paclitaxel • Cyramza (ramucirumab) • TRK-950
    8ms
    A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer (clinicaltrials.gov)
    P2, N=146, Not yet recruiting, Toray Industries, Inc
    New P2 trial • Combination therapy
    |
    CAPRIN1 (Cell Cycle Associated Protein 1)
    |
    paclitaxel • Cyramza (ramucirumab) • TRK-950